Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Arash Assadsangabi"'
Publikováno v:
Gastroenterology Research and Practice, Vol 2019 (2019)
Inflammatory bowel disease (IBD) is a chronic relapsing/remitting inflammatory illness of the gastrointestinal tract of unknown aetiology. Despite recent advances in decoding the pathophysiology of IBD, many questions regarding disease pathogenesis r
Externí odkaz:
https://doaj.org/article/2d2fce076d99425bb7020c44c0afe88d
Autor:
Marco Vincenzo Lenti, Vivien Dolby, Tanya Clark, Veronica Hall, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Rachael Walker, Karen Kemp, Simon Borg‐Bartolo, Jimmy K. Limdi, Jo Taylor, Tristan Townsend, Sree Subramanian, Daniel Storey, Arash Assadsangabi, Catherine Stansfield, Paul Smith, Debra Byrne, Annalisa De Silvestri, Christian P. Selinger
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:856-866
Autor:
Robert Clark, Yeng Ang, Maja Kopczynska, Arash Assadsangabi, Georgios Marinopoulos, Nadeem Sarwar
Publikováno v:
GastroHep. 3:12-18
Publikováno v:
Gastroenterology Research and Practice
Gastroenterology Research and Practice, Vol 2019 (2019)
Gastroenterology Research and Practice, Vol 2019 (2019)
Inflammatory bowel disease (IBD) is a chronic relapsing/remitting inflammatory illness of the gastrointestinal tract of unknown aetiology. Despite recent advances in decoding the pathophysiology of IBD, many questions regarding disease pathogenesis r
Autor:
Simon Borg-Bartolo, Suzanne Tattersall, Daniel Storey, Jimmy K. Limdi, Paul Smith, Francesca Fairhurst, Rachael Walker, Christian P. Selinger, S Subramanian, Veronica Hall, Jo Taylor, Catherine Kenneth, Marco Vincenzo Lenti, Vivien Dolby, Arash Assadsangabi, Debra Byrne, Tristan Townsend, Catherine Stansfield, Karen Kemp, Tanya Clark
Publikováno v:
Posters.
Background Ustekinumab was approved by NICE in 2016 for adults with moderate to severe CD. Real world data are required to establish effectiveness of therapy where restrictive inclusion and exclusion criteria from trials are not routinely applied. Me
Autor:
Neeraj Prasad, Ramakrishna Chaparala, Yeng Ang, George Regi, Sameul Baskind, Yeson Kim, Jen Yee Kuan, Stephen McGrath, Arash Assadsangabi
Publikováno v:
European journal of gastroenterologyhepatology. 32(7)
Aim To review the efficacy and outcomes of endoscopic resection in the diagnosis and treatment of oesophageal squamous dysplasia and early neoplasia. Methods This was a retrospective study between May 2012-2018. Twenty-one patients were treated with
Autor:
Yeng Ang, Elizabeth Ratcliffe, Jen Yee Kuan, Samuel Baskind, Yeson Kim, Arash Assadsangabi, Neeraj Prasad
Publikováno v:
Scandinavian journal of gastroenterology. 55(1)
Introduction: Endoscopic submucosal dissection (ESD) is extensively performed for the treatment of early gastric cancer (EGC) in the Eastern countries due to its favourable outcomes compare...
Autor:
C. Kenneth, Jimmy K. Limdi, Simon Borg-Bartolo, F Fairhurst, S. Tattersall, D Byrne, R Walker, V Dolby, J Taylor, Karen Kemp, Daniel Storey, S Subramanian, Arash Assadsangabi, Christian P. Selinger, Marco Vincenzo Lenti, Philip J Smith, Catherine Stansfield, V. Hall, A. De Silvestri, Tristan Townsend, Tanya Clark
Publikováno v:
Journal of Crohn's and Colitis. 15:S372-S373
Background The best choice of biological agents after failure to an anti-tumour necrosis factor (TNF)α agent in patients with Crohn’s disease (CD) is yet to be defined. Real-world data dealing with this issue are still emerging. Methods This is a
Autor:
Salil Singh, Catherine Stansfield, Eleanor Liu, Paul Smith, Anna Carter, Alex Johnston, Belle Gregg, Marco Vincenzo Lenti, Sreedhar Subramanian, Scott Levison, PJ Hamlin, Chris Probert, Daniel Storey, Ben Crooks, Elena Eliadou, Catherine Kenneth, Christian P. Selinger, Jimmy K. Limdi, Robert P. Willert, Suzanne Tattersall, Francesca Fairhurst, Arash Assadsangabi, Karen Kemp
Publikováno v:
DIGESTIVE AND LIVER DISEASE
BACKGROUND Real-life data on vedolizumab effectiveness in inflammatory bowel disease (IBD) are still emerging. Data on the comparative safety of the gut selective profile are of particular interest. AIMS To assess clinical outcome and safety in IBD p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2b5a6d4bff8745c57b42ae75773b4f